Repurposing Immunomodulatory Drugs to Combat Tuberculosis

Area of Science:

• Microbiology
• Pharmacology
• Immunology

Background:

• Tuberculosis (TB) remains a leading infectious cause of death globally.
• Current TB therapy (DOTS) faces challenges including toxicity, low efficacy, and long duration, leading to drug resistance (DR).
• Developing novel TB drugs is lengthy and expensive, necessitating alternative strategies like drug repurposing.

Purpose of the Study:

• To review repurposed drugs showing efficacy against TB and drug-resistant TB (DR-TB).
• To explore the mechanisms of action, focusing on immunomodulatory effects.
• To assess synergistic effects with existing TB drugs for adjunct therapy.

Main Methods:

• Literature review of repurposed drugs with anti-TB activity.
• Analysis of drug mechanisms, including host-directed and pathogen-targeted effects.
• Examination of studies on drug combinations and synergistic effects.

Main Results:

• Several repurposed drugs, including sulfonamides, clofazimine, linezolid, and metformin, demonstrate significant anti-TB potential.
• These drugs exhibit immunomodulatory effects, contributing to host-directed therapy.
• Synergistic effects observed when combined with existing TB drugs suggest enhanced efficacy.

Conclusions:

• Drug repurposing is a viable and essential approach for developing new anti-TB and anti-DR-TB therapies.
• Repurposed drugs offer a faster, more cost-effective alternative to novel drug development.
• Further research into synergistic combinations can accelerate the translation of repurposed drugs into clinical practice.